3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Primary Myelofibrosis
16
Polycythemia Vera
14
Myeloproliferative Disorders
11
Leukemia, Myeloid, Acute
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia
6
Myelodysplastic Syndromes
5
Hematologic Diseases
5
Myelodysplastic-Myeloproliferative Diseases
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Graft vs Host Disease
4
Bone Marrow Diseases
4
Thrombocythemia, Essential
3
Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Thrombocytosis
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Bronchiolitis Obliterans Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Preleukemia
1
Precancerous Conditions
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Interventions
Tamoxifen
10
Chemotherapy, Adjuvant
7
Radiotherapy
5
Early Intervention, Educational
5
Psychiatric Rehabilitation
4
Neoadjuvant Therapy
4
Letrozole
4
Counseling
4
Behavior Therapy
4
Anastrozole
4
Methods
3
Mass Spectrometry
3
Magnetic Resonance Spectroscopy
3
Immunohistochemistry
3
Gene Expression Profiling
3
Biopsy
3
Telemedicine
2
Taxes
2
Soybean Proteins
2
Simvastatin
2
Paclitaxel
2
Medroxyprogesterone
2
Fatty Acids, Omega-3
2
Educational Status
2
Docosahexaenoic Acids
2
Curcumin
2
Chromatography, High Pressure Liquid
2
Brachytherapy
2
telapristone acetate
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Carcinoma In Situ
×
ruxolitinib
×
Clear all
NCT02928978
2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2
Completed
84 enrolled